Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 276.06 +1.03 (+0.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today September 30, 2024 Via Benzinga Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 September 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Looking Into Alnylam Pharmaceuticals's Recent Short Interest September 26, 2024 Via Benzinga Alnylam to Webcast TTR Investor Day September 26, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Market Whales and Their Recent Bets on ALNY Options August 30, 2024 Via Benzinga $100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today August 26, 2024 Via Benzinga 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily Alnylam Stock Soars 65%: Find Out What’s Behind the Gains September 12, 2024 Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug. Via MarketBeat Exposures Product Safety Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years September 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 02, 2024 Via Benzinga Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles August 30, 2024 Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented... Via Benzinga How Is The Market Feeling About Alnylam Pharmaceuticals? August 06, 2024 Via Benzinga $100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today July 18, 2024 Via Benzinga Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations August 30, 2024 The company is hoping to rival Pfizer's approved treatment for cardiomyopathy. Via Investor's Business Daily Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress August 30, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentations at Upcoming September Investor Conferences August 28, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session August 12, 2024 Via Benzinga Peering Into Alnylam Pharmaceuticals's Recent Short Interest July 17, 2024 Via Benzinga Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years August 07, 2024 Via Benzinga The 3 Best Gene Editing Stocks to Buy in August 2024 August 07, 2024 These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. Via InvestorPlace Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 August 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 August 06, 2024 On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. Via Investor's Business Daily DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? August 04, 2024 Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... Via Benzinga Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday August 01, 2024 Via Benzinga Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity August 01, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results July 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Stock Is a Blockbuster Biopharma In the Making July 18, 2024 Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. Via InvestorPlace 35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. July 11, 2024 Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement. Via InvestorPlace 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.